Suter, Thomas; Ewer, Michael S. (2013). Cancer drugs and the heart: importance and management. European Heart Journal, 34(15), pp. 1102-1111. Oxford University Press 10.1093/eurheartj/ehs181
|
Text
ehs181.pdf - Published Version Available under License Publisher holds Copyright. Download (406kB) | Preview |
Progress in the detection and treatment of cancer has led to an impressive reduction in both mortality and morbidity. Due to their mechanism of action, however, conventional chemotherapeutics and some of the newer anti-cancer signaling inhibitors carry a substantial risk of cardiovascular side effects that include cardiac dysfunction and heart failure, arterial hypertension, vasospastic and thromboembolic ischaemia, dysrhythmia, and QT prolongation. While some of these side effects are irreversible and cause progressive cardiovascular disease, others induce only temporary dysfunction with no apparent long-term sequelae for the patient. The challenge for the cardiovascular specialist is to balance the need for life-saving cancer treatment with the assessment of risk from cancer drug-associated cardiovascular side effects to prevent long-term damage. This review discusses concepts for timely diagnosis, intervention, and surveillance of cancer patients undergoing treatment, and provides approaches to clinical uncertainties.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Suter, Thomas |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0195-668X |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Judith Liniger |
Date Deposited: |
18 Jun 2014 12:05 |
Last Modified: |
05 Dec 2022 14:34 |
Publisher DOI: |
10.1093/eurheartj/ehs181 |
PubMed ID: |
22789916 |
BORIS DOI: |
10.7892/boris.52920 |
URI: |
https://boris.unibe.ch/id/eprint/52920 |
Actions (login required)
 |
Edit item |